Physician profile
Jennifer Ford
NPI 1568604692
$3,434.91
in general payments reported to CMS, 2019-2025
30 companies · $370 in 2025
The $370 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $88.83 · 2021: $70.58 · 2022: $391 · 2023: $1,742 · 2024: $644 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,847 · Travel and Lodging: $908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,847.39 |
| Travel and Lodging | $908.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $1,121.88 | 2023 | Enseal |
| Aspira Women'S Health INC | $227.89 | 2022-2023 | Ova1 |
| Abbvie INC. | $219.35 | 2020-2025 | |
| Mayne Pharma Commercial LLC | $191.05 | 2021-2025 | |
| Exeltis, USA INC. | $161.77 | 2021-2025 | Slynd |
| Baxter Healthcare | $157.50 | 2024 | Tisseel |
| Ethicon US, LLC | $155.61 | 2019-2023 | Enseal |
| Biogen, INC. | $149.06 | 2024-2025 | Zurzuvae |
| Pfizer INC. | $133.51 | 2022-2025 | |
| Therapeuticsmd, INC. | $119.52 | 2019-2022 | |
| Astellas Pharma US INC | $108.45 | 2022-2024 | Veozah |
| Sumitomo Pharma America, INC. | $92.88 | 2024-2025 | Myfembree, Gemtesa |
| Dexcom, INC. | $86.46 | 2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $73.58 | 2024 | |
| Hologic Sales and Service, LLC | $70.13 | 2022-2025 | Aptima, Acessa Provu System, Novasure |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $65.28 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $39.96 | 2023-2024 | Gardasil 9, Gardasil |
| Novo Nordisk INC | $38.15 | 2024 | Wegovy |
| Organon LLC | $31.39 | 2023 | Nexplanon |
| Millicent US INC | $30.54 | 2024-2025 | Intrarosa |
| Gynesonics, INC. | $30.17 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Daiichi Sankyo INC. | $21.88 | 2019 | |
| Lupin INC. | $15.13 | 2019 | |
| Mission Pharmacal Company | $14.72 | 2019 | |
| Exact Sciences Corporation | $14.51 | 2025 | Cologuard Collection Kit |
| Allergan, INC. | $14.06 | 2019 | |
| Avion Pharmaceuticals | $13.52 | 2020 | |
| Medtronic, INC. | $13.48 | 2025 | V-Loc 180 |
| Meditrina | $11.78 | 2024 | |
| Amag Pharmaceuticals, INC. | $11.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.